Mutant p53 targeting by the low molecular weight compound STIMA-1.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. CCT6A promotes cell proliferation in colon cancer by targeting BIRC5 associated with p53 status.Cancer gene therapy · 2024
   Article
2. TP53 in Biology and Treatment of Osteosarcoma.Cancers · 2021
   Review
3. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors.International journal of molecular sciences · 2019
   Review
4. Smyd2 conformational changes in response to p53 binding: role of the C-terminal domain.Molecular oncology · 2019
   Article
5. Salvation of the fallen angel: Reactivating mutant p53.British journal of pharmacology · 2019
   Review

Corrections and comments

• Erratum for
  Mutant p53 targeting by the low molecular weight compound STIMA-1.2008

Authors and funding

8 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.